NeuroSense Therapeutics Warrant
NRSNW
3 hedge funds and large institutions have $18.3K invested in NeuroSense Therapeutics Warrant in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 3 closing their positions.
0.24% less ownership
Funds ownership: 2.02% → 1.78% (-0.24%)
50% less capital invested
Capital invested by funds: $36.4K → $18.3K (-$18.1K)
50% less funds holding
Funds holding: 6 → 3 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.85K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$1.75K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$422 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$22 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Hudson Bay Capital Management
Stamford,
Connecticut
| $8.68K | – | – | – |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $4.96K | -$1.75K | -12,607 | -17% |
|
|
CS
3
Clear Street
New York
| $4.63K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| – | -$1.85K | -11,588 | Closed |
|
|
5
UBS Group
Zurich,
Switzerland
| – | -$422 | -3,802 | Closed |
|
|
6
Bank of America
Charlotte,
North Carolina
| – | -$22 | -200 | Closed |
|
NRSNW Hedge Fund Activity: Q4 2023 in Review
3 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q4 2023, worth a combined $18.3K — down 50% from $36.4K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NRSNW and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Citadel Advisors, exiting entirely with an estimated $1.85K sold.
- 3 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q4 2023, down from 6 in Q3 2023.
- Funds reported $18.3K of NeuroSense Therapeutics Warrant stock for Q4 2023, down 50% quarter-over-quarter.
- 0 funds opened new NeuroSense Therapeutics Warrant positions in Q4 2023 and 3 closed out, a net change of -3 holders.
- The largest NeuroSense Therapeutics Warrant seller in Q4 2023 was Citadel Advisors, an estimated $1.85K sold.
Based on aggregated 13F filings for Q4 2023.